Density: Approximately 1.302±0.06 g/cm3 (Predicted) or 1.3±0.1 g/cm3
Boiling Point: 600.5±55.0 °C (at 760 mmHg)
Flash Point: 317.0±31.5 °C
Solubility: Soluble in DMSO (up to 5 mg/ml)
Form: Solid
Storage Conditions: Should be sealed, dried, and stored under frozen conditions at -20°C or below
Chemical Properties
pKa Value: 14.35±0.46 (Predicted)
Stability: Solutions in DMSO can be stored at -20°C for up to 1 month
Pharmacological Action
Mechanism of Action: Fruquintinib is an orally administered, highly selective, and potent tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR). It primarily blocks the activity of VEGFR-1, VEGFR-2, and VEGFR-3, thereby inhibiting the tumor's demand for new blood vessels and achieving the purpose of anti-angiogenesis and inhibiting tumor growth.
Indications: It is used for the treatment of patients with metastatic colorectal cancer (mCRC) who have previously received chemotherapy based on fluoropyrimidines, oxaliplatin, and irinotecan, as well as those who have previously received or are unsuitable for anti-VEGF or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type). Additionally, clinical studies of fruquintinib in various solid tumors such as non-small cell lung cancer (NSCLC) and gastric cancer are ongoing.
